Nathalie Gobeau

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

Alejandro Llanos‐Cuentas, Martín Casapía, Raúl Chuquiyauri et al. · The Lancet Infectious Diseases · 2018 · 139 citations · Full text

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

James McCarthy, Julie Lotharius, Thomas Rückle et al. · The Lancet Infectious Diseases · 2017 · 124 citations · Full text

DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection

Mihály Sulyok, Thomas Rückle, Alexandra Roth et al. · The Lancet Infectious Diseases · 2017 · 103 citations · Full text

Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery

Nathalie Gobeau, Rowan Stringer, Stefan Buck et al. · Pharmaceutical Research · 2016 · 61 citations

Biology, Gastroplus™ Advanced Compartmental, Early Discovery +3

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048

James McCarthy, Cristina Donini, Stephan Chalon et al. · Clinical Infectious Diseases · 2020 · 54 citations · Full text